München
13.04.26 | 08:04
0,142 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| Fr | Diamyd Medical AB (publ): Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review | 59 | GlobeNewswire (Europe) | Diamyd Medical today announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes. Following the previously reported interim analysis and... ► Artikel lesen | |
| Mi | Diamyd Medical AB (publ): Bulletin from Diamyd Medical's Extraordinary General Meeting 2026 | 250 | GlobeNewswire (Europe) | An Extraordinary general meeting of Diamyd Medical Aktiebolag (the "Company") was held on April 8, 2026.
The Extraordinary General Meeting resolved to approve the board of directors' resolution from... ► Artikel lesen | |
| 29.03. | Diamyd Medical AB (publ): Diamyd Medical updates on the interim efficacy analysis of Phase 3 DIAGNODE-3 trial | 257 | GlobeNewswire (Europe) | Diamyd Medical on Friday March 27th announced that the pre-specified interim efficacy analysis on 174 out of 321 participants of the ongoing Phase 3 DIAGNODE-3 trial yielded results that were unexpected... ► Artikel lesen | |
| 27.03. | Diamyd Medical AB: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial | 310 | GlobeNewswire (Europe) | Diamyd Medical today announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen | |
| 25.03. | Diamyd Medical AB: Quarterly Report 2 25/26 | 266 | GlobeNewswire (Europe) | September 2025 - February 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026
Precision Medicine for type 1 diabetes
Fully enrolled registrational Phase 3 program
Diamyd Medical develops a... ► Artikel lesen | |
| 23.03. | Diamyd Medical AB: Notice Of Extraordinary General Meeting In Diamyd Medical Aktiebolag | 6 | Cision News | ||
| 23.03. | Diamyd Medical AB: Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial | 461 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND... ► Artikel lesen | |
| 19.03. | Diamyd Medical AB: Diamyd Medical receives Notice of Grant in Japan for insulin-based antigen therapy patent in type 1 diabetes | 205 | GlobeNewswire (Europe) | Diamyd Medical has received a Notice of Grant in Japan for a patent covering the use of insulin-based antigens to treat individuals with type 1 diabetes who carry the HLA DR4-DQ8 genetic marker. Once... ► Artikel lesen | |
| 02.03. | DIAMYD MEDICAL AB: American Diabetes Association 86th Scientific Sessions to feature retogatein Phase 3 trial in dedicated symposium | 3 | Cision News | ||
| 24.02. | Diabetes-Studie: Diamyd Medical schließt Datenbank für Phase-3-Meilenstein ab | 1 | Investing.com Deutsch | ||
| 24.02. | Diamyd Medical completes database for phase 3 diabetes trial | 2 | Investing.com | ||
| 24.02. | Diamyd Medical AB: Diamyd Medical announces finalization of database for interim analysis in Phase 3 DIAGNODE-3 trial | 555 | GlobeNewswire (Europe) | The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical's ongoing pivotal Phase 3 trial (DIAGNODE-3) evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen | |
| 09.02. | Diamyd Medical erhält US-Zulassungsbescheid für zentrales Diabetes-Patent | 4 | Investing.com Deutsch | ||
| 09.02. | Diamyd Medical AB: Diamyd Medical receives Notice of Allowance for key retogatein US patent | 330 | PR Newswire | STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- Diamyd Medical today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent covering the... ► Artikel lesen | |
| 28.01. | Diamyd Medical AB: Quarterly Report 1 25/26 | 180 | GlobeNewswire (Europe) | September 2025 - November 2025 Diamyd Medical AB (publ), Fiscal year 2025/2026
Precision Medicine for type 1 diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen | |
| 23.01. | Diamyd Medical AB: Diamyd Medical deepens long-term manufacturing collaboration for retogatein | 262 | GlobeNewswire (Europe) | Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale... ► Artikel lesen | |
| 12.01. | Diamyd Medical AB: Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial | 244 | GlobeNewswire (Europe) | Diamyd Medical today announced that the screening period in its pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals with type 1 diabetes has been completed. Based on the... ► Artikel lesen | |
| 09.01. | Diamyd Medical AB: Diamyd Medical's lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein | 201 | GlobeNewswire (Europe) | Diamyd Medical today announced that its investigational antigen-specific immunotherapy for type 1 diabetes, commonly referred to as Diamyd, has been assigned the global non-proprietary name "retogatein"... ► Artikel lesen | |
| 29.12.25 | Diamyd Medical Secures FDA Alignment To Accelerate Phase 3 Trial Readout In Type 1 Diabetes | 1 | RTTNews | ||
| 29.12.25 | Diamyd Medical AB: Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance | 408 | PR Newswire | STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,790 | +0,84 % | Dünger-Desaster: Lieferketten-Kollaps bedroht Bayer, Nestlé, MustGrow und K+S! Wo liegt die Mega-Chance für Investoren? | Die Eskalation um den Iran hat globale Lieferketten und den Dünger- und Lebensmittelsektor in einen Ausnahmezustand versetzt, da Sanktionen und Sicherheitsrisiken den Export wichtiger Rohstoffe lahmlegen.... ► Artikel lesen | |
| NOVO NORDISK | 32,085 | +0,06 % | Deutlich höhere Dosis: Wegovy-Offensive: Novo Nordisk kontert Eli Lilly mit Mega-Dosis | © Foto: Christian Schultz/dpaNovo Nordisk geht in die Offensive: Mit einer deutlich höheren Wegovy-Dosis will der Konzern im boomenden Markt für Abnehmmedikamente verlorene Marktanteile zurückholen... ► Artikel lesen | |
| PFIZER | 23,420 | +2,07 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| ABBVIE | 175,00 | -1,35 % | AbbVie's Phase 2 Trial Shows 62.7% Response With Mirvetuximab In Platinum-Sensitive Ovarian Cancer | WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported promising results from the Phase 2 IMGN853-0420 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) in combination with carboplatin, followed... ► Artikel lesen | |
| ROCHE | 343,85 | +1,00 % | UBS stuft ROCHE HOLDINGS AG auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Roche mit einem Kursziel von 384 Franken auf "Buy" belassen. Währungseffekte dürften das erste Quartal deutlich belastet... ► Artikel lesen | |
| MERCK & CO | 102,44 | -1,06 % | Merck Launches Tender Offer To Acquire Terns Pharmaceuticals | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) said Tuesday it has commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc. (TERN). The move follows... ► Artikel lesen | |
| ABBOTT LABORATORIES | 85,62 | +0,14 % | TD Cowen reiterates Buy on Abbott Labs stock, cites Cologuard strength | ||
| DERMAPHARM | 45,000 | +4,53 % | EQS-PVR: Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Dermapharm Holding SE
Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
07.04.2026... ► Artikel lesen | |
| ZOETIS | 101,90 | +1,39 % | Zoetis Inc. to Acquire Animal Genomics Business from Neogen, Accelerating Precision Animal Health Innovation | Acquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide
PARSIPPANY... ► Artikel lesen | |
| DOCMORRIS | 6,100 | +2,87 % | "Strukturierte Nachfolgeplanung": DocMorris: Aktionär unterstützt Oberhänsli | ||
| EYEPOINT | 12,500 | +3,31 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| PENTIXAPHARM | 2,060 | 0,00 % | EQS-News: Pentixapharm Holding AG beruft Erik Merten in den Vorstand | EQS-News: Pentixapharm Holding AG
/ Schlagwort(e): Personalie
Pentixapharm Holding AG beruft Erik Merten in den Vorstand
31.03.2026 / 08:00 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 151,30 | +0,20 % | UBS raises Axsome Therapeutics price target on Auvelity outlook | ||
| DAIICHI SANKYO | 14,718 | -2,85 % | Daiichi Sankyo: FDA Grants Priority Review For Ifinatamab Deruxtecan | KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo (4568.T) and Merck's (MRK) Biologics License Application for ifinatamab deruxtecan has been accepted and granted Priority Review by the FDA for the... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,330 | -0,56 % | Trulieve to Open Medical Cannabis Dispensary in Boca Raton, Florida |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,142 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.